1. Medicine

Dysregulation of the PRUNE2/PCA3 genetic axis in human prostate cancer: from experimental discovery to validation in two independent patient cohorts

  1. Richard C Lauer
  2. Marc Barry
  3. Tracey L Smith
  4. Andrew Maltez Thomas
  5. Jin Wu
  6. Ruofei Du
  7. Ji-Hyun Lee
  8. Arpit Rao
  9. Andrey S Dobroff
  10. Marco A Arap
  11. Diana N Nunes
  12. Israel T Silva
  13. Emmanuel Dias-Neto
  14. Isan Chen
  15. Dennis J McCance
  16. Webster K Cavenee
  17. Renata Pasqualini
  18. Wadih Arap  Is a corresponding author
  1. University of New Mexico, United States
  2. University of Utah, United States
  3. Rutgers, The State University of New Jersey, United States
  4. University of São Paulo, Brazil
  5. University of Arkansas for Medical Sciences, United States
  6. University of Florida, United States
  7. Baylor College of Medicine, United States
  8. University of São Paulo, Brazil
  9. AC Camargo Cancer Center, Brazil
  10. A.C. Camargo Cancer Center, Brazil
  11. MBrace Therapeutics, United States
  12. University of California, San Diego, United States
  13. Rutgers Cancer Institute of New Jersey, United States
https://doi.org/10.7554/eLife.81929
Share this article
Cite this article
  1. Richard C Lauer
  2. Marc Barry
  3. Tracey L Smith
  4. Andrew Maltez Thomas
  5. Jin Wu
  6. Ruofei Du
  7. Ji-Hyun Lee
  8. Arpit Rao
  9. Andrey S Dobroff
  10. Marco A Arap
  11. Diana N Nunes
  12. Israel T Silva
  13. Emmanuel Dias-Neto
  14. Isan Chen
  15. Dennis J McCance
  16. Webster K Cavenee
  17. Renata Pasqualini
  18. Wadih Arap
(2023)
Dysregulation of the PRUNE2/PCA3 genetic axis in human prostate cancer: from experimental discovery to validation in two independent patient cohorts
eLife 12:e81929.
https://doi.org/10.7554/eLife.81929
  2. Download BibTeX
  3. Download .RIS

Abstract

Background: We have previously shown that the long non-coding (lnc)RNA prostate cancer associated 3 (PCA3; formerly prostate cancer antigen 3) functions as a trans-dominant negative oncogene by targeting the previously unrecognized prostate cancer suppressor gene PRUNE2 (a homolog of the Drosophila prune gene), thereby forming a functional unit within a unique allelic locus in human cells. Here we investigated the PCA3/PRUNE2 regulatory axis from early (tumorigenic) to late (biochemical recurrence) genetic events during human prostate cancer progression.

Methods: The reciprocal PCA3 and PRUNE2 gene expression relationship in paired prostate cancer and adjacent normal prostate was analyzed in two independent retrospective cohorts of clinically-annotated cases post-radical prostatectomy: a single-institution discovery cohort (n=107) and a multi-institution validation cohort (n=497). We compared the tumor gene expression of PCA3 and PRUNE2 to their corresponding expression in the normal prostate. We also serially examined clinical/pathological variables including time to disease recurrence.

Results: We consistently observed increased expression of PCA3 and decreased expression of PRUNE2 in prostate cancer compared with the adjacent normal prostate across all tumor grades and stages. However, there was no association between the relative gene expression levels of PCA3 or PRUNE2 and time to disease recurrence, independent of tumor grades and stages.

Conclusions: We concluded that upregulation of the lncRNA PCA3 and targeted downregulation of the protein-coding PRUNE2 gene in prostate cancer could be early (rather than late) molecular events in the progression of human prostate tumorigenesis but are not associated with biochemical recurrence. Further studies of PCA3/PRUNE2 dysregulation are warranted.

Funding: We received support from the Human Tissue Repository and Tissue Analysis Shared Resource from the Department of Pathology of the University of New Mexico School of Medicine and a pilot award from the University of New Mexico Comprehensive Cancer Center. RP and WA were supported by awards from the Levy-Longenbaugh Donor-Advised Fund and the Prostate Cancer Foundation. EDN reports research fellowship support from the Brazilian National Council for Scientific and Technological Development (CNPq), Brazil, and the Associação Beneficente Alzira Denise Hertzog Silva (ABADHS), Brazil. This work has been funded in part by the NCI Cancer Center Support Grants (CCSG; P30) to the University of New Mexico Comprehensive Cancer Center (CA118100) and the Rutgers Cancer Institute of New Jersey (CA072720).

Data availability

For the discovery cohort, all data generated or analyzed are included in the manuscript and source data files, except for patient-level ethnicity data. Patient-level ethnicity data is not included due to the potential for identifiability. However detailed summary ethnicity data is presented in the manuscript and in Table 1. Requests to access the patient level ethnicity data should be directed to the corresponding author with a project proposal. Source codes are also available in the supplemental source code file. For the Validation Cohort, clinicopathological patient characteristics and gene level transcription data from The Cancer Genome Atlas (TCGA) were accessed from the UCSC Xena Resource.

The following previously published data sets were used

Article and author information

Author details

  1. Richard C Lauer

    Comprehensive Cancer Center, University of New Mexico, Albuquerque, United States
    Competing interests
    No competing interests declared.

  2. Marc Barry

    Department of Pathology, University of Utah, Salt Lake City, United States
    Competing interests
    No competing interests declared.

  3. Tracey L Smith

    Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, Newark, United States
    Competing interests
    No competing interests declared.

  4. Andrew Maltez Thomas

    Department of Biochemistry, University of São Paulo, São Paulo, Brazil
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5789-3354

  5. Jin Wu

    Comprehensive Cancer Center, University of New Mexico, Albuquerque, United States
    Competing interests
    No competing interests declared.

  6. Ruofei Du

    Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, United States
    Competing interests
    No competing interests declared.

  7. Ji-Hyun Lee

    Department of Biostatistics, University of Florida, Gainesville, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6420-5150

  8. Arpit Rao

    Department of Medicine, Baylor College of Medicine, Houston, United States
    Competing interests
    No competing interests declared.

  9. Andrey S Dobroff

    Comprehensive Cancer Center, University of New Mexico, Albuquerque, United States
    Competing interests
    No competing interests declared.

  10. Marco A Arap

    Division of Urology, University of São Paulo, São Paulo, Brazil
    Competing interests
    No competing interests declared.

  11. Diana N Nunes

    Laboratory of Computational Biology, AC Camargo Cancer Center, Sao Paulo, Brazil
    Competing interests
    Diana N Nunes, The University of New Mexico filed patent applications on PRUNE2- related technology, for which Diana Nunes was an inventor (inventors: DNN, EDN, RP, and WA). Those applications were briefly optioned by MBrace Therapeutics, but the applications have since been abandoned and the agreements terminated. No payments were made to Diana Nunes, and the author has no other competing interests to declare..

  12. Israel T Silva

    Laboratory of Computational Biology, AC Camargo Cancer Center, Sao Paulo, Brazil
    Competing interests
    No competing interests declared.

  13. Emmanuel Dias-Neto

    Laboratory of Computational Biology, A.C. Camargo Cancer Center, Sao Paulo, Brazil
    Competing interests
    Emmanuel Dias-Neto, The University of New Mexico filed patent applications on PRUNE2- related technology, for which Emmanuel Dias-Neto was an inventor (inventors: DNN, EDN, RP, and WA). Those applications were briefly optioned by MBrace Therapeutics, but the applications have since been abandoned and the agreement terminated. No payments were made to Emmanuel Dias-Neto, and the author has no other competing interests to declare..

  14. Isan Chen

    MBrace Therapeutics, San Diego, United States
    Competing interests
    Isan Chen, serves as the Chief Executive Officer of MBrace Therapeutics. Mbrace did not provide financial support for the present work..

  15. Dennis J McCance

    Comprehensive Cancer Center, University of New Mexico, Albuquerque, United States
    Competing interests
    No competing interests declared.

  16. Webster K Cavenee

    Ludwig Institute for Cancer Research, University of California, San Diego, La Jolla, United States
    Competing interests
    Webster K Cavenee, is a founder and shareholder of Interleukin Combinatorial Therapies, Inc., InVaMet, Inc., and io9, LLC; none of these companies provided funds or participated in the present work. These arrangements are managed in accordance with the established institutional conflict of interest policies for the respective institution. The author received support for attending the Aspen Cancer Conference, and participated in a Leadership or fiduciary role. The author holds a Leadership or fiduciary role at Genetron Health for which they receive board fees, and are on the Board of Directors for the GBM AGILE Clinical Trial. The author has no other competing interests to declare..

  17. Renata Pasqualini

    Department of Radiation Oncology, Rutgers, The State University of New Jersey, Newark, United States
    Competing interests
    Renata Pasqualini, Reviewing editor, eLifeThe University of New Mexico filed patent applications on PRUNE2- related technology (inventors: DNN, EDN, RP, and WA). Those applications were briefly optioned by MBrace Therapeutics, but the applications have since been abandoned and the agreements terminated. RP (and WA) is a founder and equity stockholder of PhageNova Bio, Inc. and of MBrace Therapeutics, Inc.; RP also serves as a paid consultant and the Chief Scientific Officer of PhageNova Bio and as a paid consultant and member of the Board of Directors for MBrace Therapeutics. Mbrace did not provide financial support for the present work. These arrangements are managed in accordance with the established institutional conflict of interest policies for the respective institutions..

  18. Wadih Arap

    Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Newark, United States
    For correspondence
    wa116@newark.rutgers.edu
    Competing interests
    Wadih Arap, Reviewing editor, eLifeThe University of New Mexico filed patent applications on PRUNE2-related technology (inventors: DNN, EDN, RP, and WA). Those applications were briefly optioned by MBrace Therapeutics, but the applications have since been abandoned and the agreements terminated. WA is a founder and equity stockholder of PhageNova Bio, Inc. and of MBrace Therapeutics, Inc. Mbrace did not provide financial support for the present work. These arrangements are managed in accordance with the established institutional conflict of interest policies for the respective institutions..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8686-4584

Funding

National Cancer Institute (P30CA118100)

  • Richard C Lauer

National Cancer Institute (P30CA072720)

  • Renata Pasqualini
  • Wadih Arap

Levy-Longenbaugh Donor-Advised Fund

  • Renata Pasqualini
  • Wadih Arap

Prostate Cancer Foundation

  • Renata Pasqualini
  • Wadih Arap

Brazilian National Council for Scientific and Technological Development

  • Emmanuel Dias-Neto

Associação Beneficente Alzira Denise Hertzog Silva

  • Emmanuel Dias-Neto

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: For the discovery cohort, there was University of New Mexico Health Sciences Institutional Review Board (IRB) approval (HRRC15-138), and the study was carried out in accordance with the United States Common Rule. As the discovery cohort involved secondary use of archival biospecimens, the IRB waived the requirement for informed consent .

Copyright

© 2023, Lauer et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 635
    views
  • 118
    downloads
  • 2
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Richard C Lauer
  2. Marc Barry
  3. Tracey L Smith
  4. Andrew Maltez Thomas
  5. Jin Wu
  6. Ruofei Du
  7. Ji-Hyun Lee
  8. Arpit Rao
  9. Andrey S Dobroff
  10. Marco A Arap
  11. Diana N Nunes
  12. Israel T Silva
  13. Emmanuel Dias-Neto
  14. Isan Chen
  15. Dennis J McCance
  16. Webster K Cavenee
  17. Renata Pasqualini
  18. Wadih Arap
(2023)
Dysregulation of the PRUNE2/PCA3 genetic axis in human prostate cancer: from experimental discovery to validation in two independent patient cohorts
eLife 12:e81929.
https://doi.org/10.7554/eLife.81929

Share this article

https://doi.org/10.7554/eLife.81929

Categories and tags

Research organism

Further reading

    1. Immunology and Inflammation
    2. Medicine

    JAK inhibition decreases the autoimmune burden in Down syndrome

    Angela L Rachubinski, Elizabeth Wallace ... Joaquín M Espinosa
    Research Article

    Background:

    Individuals with Down syndrome (DS), the genetic condition caused by trisomy 21 (T21), display clear signs of immune dysregulation, including high rates of autoimmunity and severe complications from infections. Although it is well established that T21 causes increased interferon responses and JAK/STAT signaling, elevated autoantibodies, global immune remodeling, and hypercytokinemia, the interplay between these processes, the clinical manifestations of DS, and potential therapeutic interventions remain ill defined.

    Methods:

    We report a comprehensive analysis of immune dysregulation at the clinical, cellular, and molecular level in hundreds of individuals with DS, including autoantibody profiling, cytokine analysis, and deep immune mapping. We also report the interim analysis of a Phase II clinical trial investigating the safety and efficacy of the JAK inhibitor tofacitinib through multiple clinical and molecular endpoints.

    Results:

    We demonstrate multi-organ autoimmunity of pediatric onset concurrent with unexpected autoantibody-phenotype associations in DS. Importantly, constitutive immune remodeling and hypercytokinemia occur from an early age prior to autoimmune diagnoses or autoantibody production. Analysis of the first 10 participants to complete 16 weeks of tofacitinib treatment shows a good safety profile and no serious adverse events. Treatment reduced skin pathology in alopecia areata, psoriasis, and atopic dermatitis, while decreasing interferon scores, cytokine scores, and levels of pathogenic autoantibodies without overt immune suppression.

    Conclusions:

    JAK inhibition is a valid strategy to treat autoimmune conditions in DS. Additional research is needed to define the effects of JAK inhibition on the broader developmental and clinical hallmarks of DS.

    Funding:

    NIAMS, Global Down Syndrome Foundation.

    Clinical trial number:

    NCT04246372.

    1. Immunology and Inflammation
    2. Medicine

    NK cell exhaustion in Wilson’s disease revealed by single-cell RNA sequencing predicts the prognosis of cholecystitis

    Yong Jin, Jiayu Xing ... Qingsheng Yu
    Research Article

    Metabolic abnormalities associated with liver disease have a significant impact on the risk and prognosis of cholecystitis. However, the underlying mechanism remains to be elucidated. Here, we investigated this issue using Wilson’s disease (WD) as a model, which is a genetic disorder characterized by impaired mitochondrial function and copper metabolism. Our retrospective clinical study found that WD patients have a significantly higher incidence of cholecystitis and a poorer prognosis. The hepatic immune cell landscape using single-cell RNA sequencing showed that the tissue immune microenvironment is altered in WD, mainly a major change in the constitution and function of the innate immune system. Exhaustion of natural killer (NK) cells is the fundamental factor, supported by the upregulated expression of inhibitory receptors and the downregulated expression of cytotoxic molecules, which was verified in clinical samples. Further bioinformatic analysis confirmed a positive correlation between NK cell exhaustion and poor prognosis in cholecystitis and other inflammatory diseases. The study demonstrated dysfunction of liver immune cells triggered by specific metabolic abnormalities in WD, with a focus on the correlation between NK cell exhaustion and poor healing of cholecystitis, providing new insights into the improvement of inflammatory diseases by assessing immune cell function.

    1. Cell Biology
    2. Medicine

    Long non-coding RNA Malat1 fine-tunes bone homeostasis and repair by orchestrating cellular crosstalk and β-catenin-OPG/Jagged1 pathway

    Yongli Qin, Jumpei Shirakawa ... Baohong Zhao
    Research Article

    The IncRNA Malat1 was initially believed to be dispensable for physiology due to the lack of observable phenotypes in Malat1 knockout (KO) mice. However, our study challenges this conclusion. We found that both Malat1 KO and conditional KO mice in the osteoblast lineage exhibit significant osteoporosis. Mechanistically, Malat1 acts as an intrinsic regulator in osteoblasts to promote osteogenesis. Interestingly, Malat1 does not directly affect osteoclastogenesis but inhibits osteoclastogenesis in a non-autonomous manner in vivo via integrating crosstalk between multiple cell types, including osteoblasts, osteoclasts, and chondrocytes. Our findings substantiate the existence of a novel remodeling network in which Malat1 serves as a central regulator by binding to β-catenin and functioning through the β-catenin-OPG/Jagged1 pathway in osteoblasts and chondrocytes. In pathological conditions, Malat1 significantly promotes bone regeneration in fracture healing. Bone homeostasis and regeneration are crucial to well-being. Our discoveries establish a previous unrecognized paradigm model of Malat1 function in the skeletal system, providing novel mechanistic insights into how a lncRNA integrates cellular crosstalk and molecular networks to fine tune tissue homeostasis, remodeling and repair.